Thrombotic microangiopathy and pregnancy

Česká verzia

Authors: M. Koucký ¹; A. Toman ³; R. Ryšavá ²; A. Pařízek ¹
Authors place of work: Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. A. Martan, DrSc. ¹; Klinika nefrologie 1. LF UK a VFN, Praha, přednosta prof. MUDr. V. Tesař, MBA, DrSc. ²; Gynekologicko-porodnické oddělení Oblastní nemocnice, Kolín, primář MUDr. A. Toman, MBA ³
Published in the journal: Ceska Gynekol 2020; 85(1): 18-28
Category:

Summary

Objective: The aim of this study is to draw attention to a nosological unit called thrombotic microangiopathy (TMA). This syndrome represents a serious pathological condition characterized by microangiopathic haemolytic anemia (MAHA), thrombocytopenia and various organ dysfunction. Patients are most often presented with symptoms of the HELLP syndrome but if the clinical picture is not restituted within 48–72 hours after delivery, other TMAs should be considered.

Setting: Department of Obstetrics and Gynecology, 1st Medical Faculty and General Teaching Hospital Prague; Clinic of Nephrology, 1st Medical Faculty and General Teaching Hospital Prague; Department of Obstetrics and Gynecology, Regional Hospital Kolín.

Design: Review article and case reports.

Methods: Review of the literature and description of two cases of TMA.

Conclusion: The authors present a basic overview of the issue of TMA, which requires interdisciplinary cooperation of obstetricians, anesthesiologists, nephrologists and hematologists. In the second part of the article, we present two TMA case reports and finally show the differential diagnostic and therapeutic scheme as agreed by the authorities in the field.

Keywords:

HELLP syndrome – eculizumab – thrombotic microangiopathy – atypical hemolytic uremic syndrome – hemolytic uremic syndrome – thrombotic thrombocytopenic purpura – acute fatty liver of pregnancy

Zdroje

1. ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia. Obstet Gynecol, 2019, 133(1):e1.

2. Afshar-Kharghan, V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program, 2016, 1, p. 217–225.

3. Ahmed, A. Evidence-based revised view of the pathophysiology of preeclampsia. Adv Exp Med Biol, 2017, 956, p. 355–374.

4. Basit, S., Wohlfahrt, J., Boyd, HA. Pre-eclampsia and risk of dementia later in life: nationwide cohort study. BMJ, 2018, 363, k4109.

5. Berger, BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J, 2018, 12(3), p. 338–347.

6. Bruel, A., Kavanagh, D., Noris, M, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol, 2017, 12(8), p. 1237–1247.

7. Burwick, RM., Moyle, KA., Gupta, M. Pregnancy-associated atypical hemolytic uremic syndrome: some answers. Am J Obstet Gynecol, 2019, 220(1), Suppl., p. S397–S398.

8. Fakhouri, F., Zuber, J., Frémeaux-Bacchi, V., Loirat, C. Haemolytic uraemic syndrome. Lancet, 2017, 390(10095), p. 681–696.

9. Fraser, R. Decidual natural killer cells regulate vessel stability: implications for impaired spiral artery remodelling. J Reprod Immunol, 2015, 110, p. 54–60.

10. Fyfe-Brown, A., Clarke, G., Nerenberg, K., et al. Management of pregnancy-associated thrombotic thrombocytopenia purpura. AJP Rep, 2013, 3(1), p. 45.

11. Garcia Salazar, MD., Mobley, Y., Henson, J., et al. Early pregnancy immune biomarkers in peripheral blood may predict preeclampsia, J Reprod Immunol, 2018, 125, p. 25–31.

12. Gasser, C., Gautier, E., Steck, A., et al. Hämolytisch urämische Syndrom: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wchschr, 1955, 85, p. 905–909.

13. Haram, K., Svendsen, E., Abildgaard, U. The HELLP syndrome: Clinical issues and management. A review. BMC Pregnancy Childbirth, 2009, 9, p. 8.

14. Hayslett, JP. Interaction of renal disease and pregnancy. Kidney Int, 1984, 25(3), p. 579.

15. Ibdah, JA., Bennett, MJ., Rinaldo, P., et alk. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med, 1999, 340(22), p. 1723.

16. Joly, BS., Coppo, P., Veyradier, A. Thrombotic thrombocytopenic purpura. Blood, 2017, 129(21), p. 2836–2846.

17. Kappler, S., Ronan-Bentle, S., Graham, A. Thrombotic microangiopathies (TTP, HUS, HELLP). Hematol Oncol Clin North Am, 2017, 31(6), p. 1081–1103.

18. Knight, M., Nelson-Piercy, C., Kurinczuk, JJ., et al. UK Obstetric Surveillance System. A prospective national study of acute fatty liver of pregnancy in the UK. Gut, 2008, 57(7), p. 951.

19. Legendre, CM., Licht, C., Muus, P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med, 2013, 368(23), p. 2169–2181.

20. Liu, J., Ghaziani, TT., Wolf, JL. Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis, and management. Am J Gastroenterol, 2017, 112(6), p. 838–846.

21. Martin, JN Jr., Rinehart, BK., May, WL., et al. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol, 1990, 180, p. 1373–1384.

22. Minakami, H., Morikawa, M., Yamada, T., et al. Differentiation of acute fatty liver of pregnancy from syndrome of hemolysis, elevated liver enzymes and low platelet counts. J Obstet Gynaecol Res, 2014, 40(3), p. 641–649.

23. Moffett, A. NK cell allorecognition. Nat Rev Immunol, 2017, 17(8), p. 466.

24. Moffett, A., Chazara, O., Colucci, F., Johnson, MH. Variation of maternal KIR and fetal HLA-C genes in reproductive failure: too early for clinical intervention. Reprod Biomed Online, 2016, 33(6), p. 763–769.

25. Noris, M., Caprioli, J., Bresin, E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol, 2010, 5(10), p. 1844–1859.

26. Noris, M., Mescia, F., Remuzzi, G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol, 2012, 8(11), p. 622–633.

27. Noris, M., Remuzzi, G. Atypical hemolytic-uremic syndrome. N Engl J Med, 2009, 361, p. 1676–1687.

28. Nürnberger, J., Philipp, T., Witzke, O., et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med, 2009, 360(5), p. 542–544.

29. Raina, R., Grewal, MK., Radhakrishnan, Y., et al. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis, 2019, 12, p. 183–204.

30. Rosove, MH. Thrombotic microangiopathies. Semin Arthritis Rheum, 2014, 43(6), p. 797–805.

31. Scully, M., Hunt, BJ., Benjamin, S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol, 2012, 158, p. 323–335.

32. Scully, M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost, 2016, 42(7), p. 774–779.

33. Stella, CL., Dacus, J., Guzman, E., et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol, 2009, 200(4), p. 381.e1–6.

34. Stefanovic, V. The extended use of eculizumab in pregnancy and complement activation? Associated diseases affecting maternal, fetal and neonatal kidneys – the future is now? J Clin Med, 2019, 8(3), pii: E407.

35. Theilen, LH., Meeks, H., Fraser, A., et al. Long-term mortality risk and life expectancy following recurrent hypertensive disease of pregnancy. Am J Obstet Gynecol, 2018, pii: S0002-9378(18)30279-5.

36. Thomas, MR., Robinson, S., Scully, MA. How we manage thrombotic microangiopathies in pregnancy. Br J Haematol, 2016, 173(6), p. 821–830.

37. Trávniková, M., Gumulec, J., Kořístek, Z., et al. HELLP syndrome requiring therapeutic plasma exchange due to progression to multiple organ dysfunction syndrome with predominant encephalopathy, respiratory and renal insufficiency. Čes Gynek, 2017, 82(3), p. 202–205.

38. Vaught, AJ., Braunstein, EM., Jasem, J., et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight, 2018, 3(6). pii: 99128.

39. Vlk, R., Procházka, M. Hypertenzní onemocnění v těhotenství. Čes Gynek, 2018, 83, p. 145–154.

40. Zipfel, PF. Thrombotic microangiopathies: new insights and new challenges. Curr Opinion Nephrol Hypertens, 2010, 4, p. 372–378.